A. Sobrero

发表

Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

R. Greil, R. Labianca, L. Collette, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

M. Piccart, U. Dafni, E. D. de Vries, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Correcetions to "A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)".

M. Piccart, U. Dafni, E. D. de Vries, 2017 .

Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials

R. Schilsky, J. Marshall, P. Rougier, 2004, British Journal of Cancer.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

J Ricke, T Maughan, W. Oyen, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab.

M. Moroni, G. Colucci, M. Nichelatti, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of Clinical Efficacy of New Medical Treatments in Advanced Colorectal Cancer. Results of a Workshop Organized by the Eortc Gitccg

R. Labianca, D. Kerr, W. Scheithauer, 1998 .

Sequence-dependent synergism between dichloromethotrexate and 5-fluorouracil in a human colon carcinoma cell line.

J. Bertino, A. Sobrero, 1983, Cancer research.

Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA Phase 3 Randomized Trial.

R. Labianca, L. Rimassa, P. Marchetti, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.

Joon-Oh Park, M. Buyse, Y. Bang, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Liver targeting of autologous erythrocytes loaded with doxorubicin.

E. Zocchi, M. Tonetti, A. Sobrero, 1991, European journal of cancer.

Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy.

A. Santoro, L. Rimassa, M. Tronconi, 2010, European journal of cancer.

Decreased folylpolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance.

J. Bertino, A. Sobrero, Y. M. Chang, 1993, Cancer research.

The neo-adjuvant, surgical and adjuvant treatment of gastric adenocarcinoma. Current expert opinion derived from the Seventh World Congress on Gastrointestinal Cancer, Barcelona, 2005.

R. Labianca, K. Haustermans, E. Van Cutsem, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer

W. Scheithauer, H. Lenz, J. Nippgen, 2020, The oncologist.

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

E. Van Cutsem, F. Lordick, C. Punt, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Impact on quality of life of adding cetuximab to irinotecan in patients who have failed prior oxaliplatin-based therapy: The EPIC trial

W. Scheithauer, A. Zubel, J. Maurel, 2007 .

A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer

F. Boccardo, S. Negrini, S. Sciallero, 2013, Cancer Immunology, Immunotherapy.

Locoregional Tumor Therapy

T. Vogl, F. Orsi, A. Sobrero, 2018, Springer International Publishing.

Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST).

J. Hartmann, A. Zaniboni, T. Price, 2010 .

Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008.

N. Pavlakis, D. Haller, D. Cunningham, 2010, Clinical colorectal cancer.

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making.

R. Labianca, D. Kerr, I. Nagtegaal, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).

R. Salazar, E. Van Cutsem, G. Bodoky, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of progression‐free survival, overall survival, and patient‐reported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy

E. Van Cutsem, H. Kalofonos, M. Peeters, 2009, Cancer.

First-line single-agent cetuximab in patients with advanced colorectal cancer.

S. Siena, S. Sciallero, S. Mammoliti, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

The handling of metastatic colorectal cancer.

A. Sobrero, G. Fornarini, A. Guglielmi, 2005, Annals of Oncology.

Bevacizumab plus fluorouracil: the value of being part of a developing story.

P. Bruzzi, A. Sobrero, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer.

T. Conroy, E. Van Cutsem, J. Tabernero, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Relevance of Scheduling to the Efficacy of 5-Fluorouracil Alone and in Combination with Other Agents

O. Belvedere, A. Sobrero, 2003 .

Schedule specific biochemical modulation of 5-fluorouracil in advanced colorectal cancer: a randomized study. GISCAD, IOR and collaborating centers.

S. Barni, R. Labianca, L. Frontini, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Thymidylate synthase protein expression in primary colorectal cancer compared with the corresponding distant metastases and relationship with the clinical response to 5-fluorouracil.

F. Maley, D. Debernardis, A. Sobrero, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Synergism and lack of cross-resistance between short-term and continuous exposure to fluorouracil in human colon adenocarcinoma cells.

J. Bertino, R. Rosso, A. Sobrero, 1993, Journal of the National Cancer Institute.

The Optimal Duration of Adjuvant Therapy for Stage III Colon Cancer: the European Perspective

G. Bregni, A. Sobrero, S. E. Rebuzzi, 2019, Current Treatment Options in Oncology.

Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials.

R. Labianca, M. Buyse, L. Påhlman, 2007, Journal of the National Cancer Institute.

Adjuvant therapy for colon cancer: 12 months, 9 months, 6 months ... why not 3 months?

S. Sciallero, A. Sobrero, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Chemotherapy: which drug and when?

A. Sobrero, E. Bennicelli, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomized trial of TAS-102 for refractory metastatic colorectal cancer.

Marc Peeters, Yasuhiro Shimada, Ben Tran, 2015, The New England journal of medicine.

Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials

Y. Shimada, E. Van Cutsem, N. Sugimoto, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.

Tae Won Kim, N. Segal, M. Fakih, 2019, The Lancet. Oncology.

Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study

E. Van Cutsem, H. Lenz, J. Stoehr, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Mechanism of action of fluoropyrimidines: relevance to the new developments in colorectal cancer chemotherapy.

F. Puglisi, F. Grossi, A. Sobrero, 2000, Seminars in oncology.

Scheduling of fluorouracil: a forget-me-not in the jungle of doublets.

A. Sobrero, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.

E. Van Cutsem, A. Santoro, J. Douillard, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

5-fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low-cost chemotherapy for advanced colorectal cancer

R. Labianca, E. Cortesi, F. Grossi, 2001, British Journal of Cancer.

Medical Oncology: IROX as second-line therapy for metastatic colorectal cancer

A. Sobrero, 2009, Nature Reviews Clinical Oncology.

Highlights from the 2008 Gastrointestinal Cancers Symposium.

A. Sobrero, G. Aprile, 2009, European journal of cancer care.

‘ ‘ Improving outcomes in metastatic colorectal cancer : is there still room for improvement ?

A. Sobrero, 2018 .

TAS-102 in refractory colorectal cancer: caution is needed.

A. Sobrero, 2012, The Lancet. Oncology.

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.

R. Greil, B. Chauffert, S. Barni, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.

A. Carrato, E. Van Cutsem, M. Ducreux, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Vatalanib in advanced colorectal cancer: two studies with identical results.

P. Bruzzi, A. Sobrero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase IV Study of Bevacizumab in Combination with Infusional Fluorouracil, Leucovorin and Irinotecan (FOLFIRI) in First-Line Metastatic Colorectal Cancer

S. Clarke, P. Mainwaring, S. Ackland, 2008, Oncology.

The role of methotrexate in the chemotherapy of gestational trophoblastic neoplasms.

J. Bertino, A. Sobrero, 1984, Advances in experimental medicine and biology.

Molecular markers of chemotherapy in advanced colorectal cancer: back to square one.

A. Sobrero, 2009, European journal of cancer.

Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study.

T. Conroy, E. Van Cutsem, J. Tabernero, 2005, Clinical colorectal cancer.

Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.

C. Tournigand, Z. Wainberg, J. Bendell, 2013, Clinical colorectal cancer.

CME Information REAL-LIFE DECISIONS Clinical Investigators Provide Their Perspectives on Actual Patients with Metastatic Colorectal , Gastric and Pancreatic Cancer

H. Lenz, E. Kwak, A. Sobrero, 2016 .

Exploring the roles of combination and sequential strategies in palliative CRC care

A. Sobrero, 2008 .

New directions in the treatment of colorectal cancer: a look to the future.

D. Kerr, E. Van Cutsem, M. Aapro, 2000, European journal of cancer.

A tribute to biologics in advanced colorectal cancer treatment.

A. Sobrero, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Objectives of chemotherapy for unresectable liver metastases: Best response or resection?

A. Sobrero, A. Pessino, F. Cian, 2007 .

Maintenance therapy in advanced colorectal cancer, yes or no? Ask the laboratory.

A. Sobrero, A. Damiani, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Prospective randomised trial comparing fluorouracil versus doxifluridine for the treatment of advanced colorectal cancer.

D. Amadori, M. Marangolo, V. Lorusso, 1993, European journal of cancer.

Resistance to 5-fluorouracil and 5-fluoro-2'-deoxyuridine mechanisms and clinical implications.

R. Rosso, A. Sobrero, A. Guglielmi, 1990, Journal of chemotherapy.

Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group.

R. Labianca, R. Schilsky, J. Berlin, 2018, European journal of cancer.

O-0022RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF TAS-102 VS. PLACEBO, WITH BEST SUPPORTIVE CARE (BSC), IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) REFRACTORY TO STANDARD THERAPIES (RECOURSE)

Y. Shimada, Mamoru Ito, H. Lenz, 2014 .

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

D. Sargent, M. Ychou, R. Goldberg, 2013, The Lancet.

E. Van Cutsem, H. Lenz, B. Peil, 2019, Clinical colorectal cancer.

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study.

M. Ychou, E. Van Cutsem, A. Grothey, 2018, The oncologist.

Alternating versus continuous "FOLFIRI" in advanced colorectal cancer (ACC): A randomized "GISCAD" trial.

S. Barni, R. Labianca, M. Marangolo, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies

C. Bordignon, S. Sciallero, S. Mammoliti, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant Systemic Therapies in Patients with Colorectal Cancer: An Audit on Clinical Practice in Italy

S. Barni, R. Labianca, G. Luporini, 2005, Tumori.

The need for a new fluoropyrimidine in advanced gastric cancer treatment

D. Haller, J. Douillard, Yasuhide Yamada, 2012 .

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers

M. Piccart, U. Dafni, E. D. de Vries, 2016, ESMO Open.

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group

R. Labianca, A. Benson, J. Zalcberg, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line single-agent cetuximab in patients with advanced colorectal cancer.

S. Siena, S. Sciallero, S. Mammoliti, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tamoxifen-induced total alopecia.

F. Puglisi, A. Sobrero, G. Aprile, 2001, Annals of internal medicine.

Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomized trial.

R. Labianca, L. Cavanna, G. Beretta, 2021, European journal of cancer.

Early-Onset Colorectal Adenocarcinoma in the IDEA Database: Treatment Adherence, Toxicities, and Outcomes With 3 and 6 Months of Adjuvant Fluoropyrimidine and Oxaliplatin

R. Labianca, J. Meyerhardt, E. Oki, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trial.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Informed decisions regarding microsatellite instability testing: need for an intention-to-screen analysis.

S. Sciallero, A. Sobrero, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Current controversies in the adjuvant therapy of colon cancer.

A. Sobrero, A. Guglielmi, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

The Potential Role of Tomudex in the Treatment of Advanced Colorectal Cancer

A. Sobrero, 1997, Tumori.

Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules.

Joseph, J. Bertino, A. Sobrero, 1992, Cancer research.

Prognostic and predictive molecular biomarkers in advanced colorectal cancer.

A. Sobrero, V. Martelli, A. Pastorino, 2022, Pharmacology & therapeutics.

Changes in the Salivary Metabolic Profile of Generalized Periodontitis Patients after Non-surgical Periodontal Therapy: A Metabolomic Analysis Using Nuclear Magnetic Resonance Spectroscopy

L. Tenori, G. Berta, A. Sobrero, 2020, Journal of clinical medicine.

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

PLS. plenary session

C. Obasaju, C. Gridelli, L. Sequist, 2012 .

Fatigue: a main component of anemia symptomatology.

O. Belvedere, F. Puglisi, F. Grossi, 2001, Seminars in oncology.

The hard road to ranking the clinical benefit of antineoplastic agents: ESMO Award 2016 presentation

A. Sobrero, 2017, ESMO Open.

Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

E. Van Cutsem, F. Lordick, C. Punt, 2014 .

P-149Impact of sequence of biologic therapies on overall survival (OS) in patients with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC): an exploratory, retrospective pooled analysis

J. Douillard, M. Valladares-Ayerbes, F. Rivera, 2016 .

Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.

Edward J. Kim, P. Philip, J. Lacy, 2020, The lancet. Gastroenterology & hepatology.

Updated analysis of KRAS/NRAS and BRAF mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).

F. Lordick, C. Punt, M. Ducreux, 2014 .

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Marc Peeters, Hua Yu, Gregory Wilson, 2015, Clinical Cancer Research.

Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.

J. Ajani, E. Van Cutsem, G. Bodoky, 2020, European journal of cancer.

Clinical Calculator for Early Mortality in Metastatic Colorectal Cancer: An Analysis of Patients From 28 Clinical Trials in the Aide et Recherche en Cancérologie Digestive Database.

Daniel J Sargent, Christophe Tournigand, Eduardo Diaz-Rubio, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER2 Amplification and Anti-EGFR Sensitivity in Advanced Colorectal Cancer.

G. Bregni, S. Sciallero, A. Sobrero, 2019, JAMA oncology.

3003 ORAL Cetuximab plus irinotecan in patients (pts) with metastatic colorectal cancer (mCRC) failing prior oxaliplatin-based therapy: the EPIC trial

W. Scheithauer, H. Lenz, A. Zubel, 2007 .

Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC).

W. Scheithauer, A. Zubel, J. Maurel, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-007Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study

J. Ajani, G. Bodoky, Z. Wainberg, 2016 .

Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2 positive advanced or metastatic gastric (A/MGC), esophageal (EAC), or gastroesophageal (GEJ) adenocarcinoma: The LOGiC trial.

Joon-Oh Park, M. Buyse, Y. Bang, 2013 .

Medical Treatment of Colorectal Cancer in Elderly (>70 Years): Giscad Experience and Future Perspectives

S. Barni, R. Labianca, G. Luporini, 2002, Tumori.

Genetic markers for toxicity of adjuvant oxaliplatin and fluoropyrimidines in the phase III TOSCA trial in high-risk colon cancer patients

S. Barni, R. Labianca, L. Frontini, 2014, Scientific Reports.

LBA13PHASE III RECOURSE TRIAL OF TAS-102 VS. PLACEBO, WITH BEST SUPPORTIVE CARE (BSC), IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) REFRACTORY TO STANDARD THERAPIES

Y. Shimada, J. Tabernero, B. Tran, 2014 .

Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC).

F. Lordick, M. Ducreux, Y. Hotko, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second-line therapy for advanced colorectal cancer.

A. Sobrero, A. Guglielmi, 2007, Gastrointestinal cancer research : GCR.

Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration.

R. Labianca, J. Meyerhardt, D. Sargent, 2017 .

A need to simplify informed consent documents in cancer clinical trials. A position paper of the ARCAD Group

R. Labianca, A. Benson, J. Zalcberg, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Capecitabine in combination with oxaliplatin as first line therapy for patients (pts) with advanced or metastatic colorectal cancer (ACRC): preliminary results of an international multicenter phase II study

T. Conroy, J. Tabernero, A. Figer, 2001 .

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

R. Labianca, J. Meyerhardt, M. Buyse, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Sunitinib as second-line treatment for advanced gastric cancer: preliminary results from a phase II study

Y. Bang, Yoon-Koo Kang, H. Chung, 2007 .

Small Molecule Inhibitors of Tyrosine Kinase: Waiting for the Good News in Colorectal Cancer as Well

A. Sobrero, V. Andretta, 2008, Oncology Research and Treatment.

TAS-102 versus placebo plus best supportive care in patients with metastatic colorectal cancer refractory to standard therapies: Final survival results of the phase III RECOURSE trial.

H. Lenz, J. Tabernero, B. Tran, 2016 .

Phase II LAPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (G) for patients with locally advanced pancreatic cancer (LAPC).

P. Philip, J. Lacy, P. Hammel, 2018 .

Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

Patient-reported outcome (PRO)-assessed clinical benefit with panitumumab (Pmab) in metastatic colorectal cancer (mCRC) patients (pts)

B. Neyns, Y. Humblet, M. Peeters, 2007 .

Phase II Trial of Panitumumab in Combination with Oxaliplatin and Capecitabine Chemotherapy as 1st Line Therapy in Patients with Colorectal Cancer and Advanced Liver Metastases: The Metapan Study

M. Aglietta, S. Cascinu, S. Siena, 2012 .

Current strategies to reduce cisplatin toxicity.

R. Rosso, A. Sobrero, A. Guglielmi, 1990, Journal of chemotherapy.

Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).

R. Labianca, V. Torri, T. Yamanaka, 2019, Journal of Clinical Oncology.

Assessment of Duration and Effects of 3 vs 6 Months of Adjuvant Chemotherapy in High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial.

R. Labianca, L. Rimassa, P. Marchetti, 2020, JAMA oncology.

Reply to the letter to the editor: 'The hard road to patient-centered care: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?' By P. Trendsz et al.

A. Sobrero, J. Douillard, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

LBA21_PRProspective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): Updated results of IDEA (International Duration Evaluation of Adjuvant chemotherapy)

R. Labianca, J. Meyerhardt, D. Sargent, 2017 .

FOLFOX4/XELOX in stage II–III colon cancer: Efficacy results of the Italian three or six colon adjuvant (TOSCA) trial.

R. Labianca, L. Rimassa, P. Marchetti, 2017 .

Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.

S. Barni, R. Labianca, L. Rimassa, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Taxane-induced nail changes: incidence, clinical presentation and outcome.

B. Piraccini, A. Tosti, F. Puglisi, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial

J. Hecht, Y. Bang, M. Sawyer, 2017, JAMA oncology.

Sequence-dependent enhancement of HCT-8 cell kill by trimetrexate and fluoropyrimidines: implications for the mechanism of this interaction.

J. Bertino, A. Nicolin, R. Rosso, 1989, European Journal of Cancer and Clinical Oncology.

Time-dependent interactions between 5-fluorouracil and mitomycin C on a human colon carcinoma cell line, HCT-8, in vitro.

A. Nicolin, R. Rosso, A. Sobrero, 1989, European journal of cancer & clinical oncology.

Molecular characterization of established human colon carcinoma cell lines (HCT-8) made resistant to 5-fluorouracil by different selection schedules.

L. Papucci, N. Schiavone, S. Capaccioli, 2006, Oncology research.

Onset of neutropenia as an indicator of treatment response in the phase 3 RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo in patients with metastatic colorectal cancer.

H. Lenz, B. Tran, R. Mayer, 2017 .

PD-0034POPULATION PHARMACOKINETICS ANALYSIS OF REGORAFENIB AND ITS ACTIVE METABOLITES FROM THE PHASE III CORRECT STUDY OF METASTATIC COLORECTAL CANCER

M. Ychou, J. Tabernero, A. Grothey, 2013 .

Immunomodulatory switch maintenance therapy in metastatic colorectal carcinoma: The phase III IMPALA study.

C. Tournigand, W. Scheithauer, R. Salazar, 2016 .

Enhancement of trimetrexate cytotoxicity in vitro and in vivo by carboxypeptidase G2.

J. Bertino, R. Sherwood, A. Sobrero, 1989, Cancer research.

Mutational analysis of biomarker samples from the CORRECT study: Correlating mutation status with clinical response to regorafenib

M. Ychou, R. Goldberg, H. Lenz, 2013 .

The Amount of Evidence Needed to Support ERBB2 as a Biomarker for Resistance to EGFR Inhibitors in Metastatic Colorectal Cancer-In Reply.

G. Bregni, S. Sciallero, A. Sobrero, 2019, JAMA oncology.

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC--A Randomized Phase III Trial.

Joon-Oh Park, M. Buyse, Y. Bang, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Information given to cancer patients on diagnosis, prognosis and treatment: the clinical oncologist's perspective.

O. Belvedere, A. Minisini, F. Grossi, 2004, European journal of cancer.

Defective facilitated diffusion of nucleosides, a primary mechanism of resistance to 5-fluoro-2'-deoxyuridine in the HCT-8 human carcinoma line.

J. Bertino, R. Moir, R. Moir, 1985, Cancer research.

Effects of High-Dose Methotrexate and Leucovorin on Murine Hemopoietic Stem Cells1

A. Sobrero, I. Pannacciulli, G. Massa, 2006 .

6584 A phase III study of CapeOx +/− lapatinib in HER2 positive locally-advanced/metastatic upper gastrointestinal adenocarcinoma: interim safety results

Joon-Oh Park, M. Koehler, J. Hecht, 2009 .

Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC).

C. Tournigand, J. Bendell, A. Ricart, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lack of correlation between immunohistochemical expression of E2F-1, thymidylate synthase expression and clinical response to 5-fluorouracil in advanced colorectal cancer.

O. Belvedere, F. Puglisi, C. di Loreto, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care.

J. Blay, G. Demetri, E. Van Cutsem, 2014, The oncologist.

Time course of regorafenib-associated adverse events in the phase III CORRECT study.

D. Sargent, M. Ychou, R. Goldberg, 2013 .

528PAFLIBERCEPT + FOLFIRI FOR TREATMENT OF METASTATIC COLORECTAL CANCER AFTER OXALIPLATIN FAILURE: 4TH INTERIM SAFETY DATA FROM THE GLOBAL AFLIBERCEPT SAFETY AND QUALITY-OF-LIFE PROGRAM (ASQOP/AFEQT STUDIES).

V. Heinemann, J. Taieb, A. Sobrero, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Leucovorin Protection on Pluripotent Hemopoietic Stem Cells in Mice Treated with High-Dose Methotrexate

F. d'Amore, A. Sobrero, I. Pannacciulli, 1984, Tumori.

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.

E. Van Cutsem, A. Benson, J. Tabernero, 2015, European journal of cancer.

Mechanism of Fluorouracil Resistance Decreased Folylpolyglutamate Synthetase Expression : A Novel Updated

J. Bertino, Yu-Ming Chang, A. Sobrero, 2006 .

Clinical aspects of drug resistance.

J. Bertino, A. Sobrero, 1986, Cancer surveys.

The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus.

E. Van Cutsem, L. Rubbia‐Brandt, J. Tabernero, 2012, The oncologist.

Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

E. Van Cutsem, F. Lordick, C. Punt, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fluorouracil in colorectal cancer--a tale of two drugs: implications for biochemical modulation.

J. Bertino, A. Sobrero, C. Aschele, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alternating bolus and continuous infusion 5-fluorouracil: a strategy to overcome resistance to this fluoropyrimidine in advanced colorectal cancer patients

F. Grossi, A. Sobrero, A. Guglielmi, 2004, Cytotechnology.

5-Fluorouracil may have different mechanisms of action depending on the dose schedule: clinical implications

J. Bertino, R. Rosso, A. Sobrero, 1994 .

Urgent need for a new staging system in advanced colorectal cancer.

M. Choti, E. Van Cutsem, B. Nordlinger, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Analysis of circulating DNA and protein biomarkers to predict the clinical activity of regorafenib and assess prognosis in patients with metastatic colorectal cancer: a retrospective, exploratory analysis of the CORRECT trial.

D. Sargent, M. Teufel, M. Ychou, 2015, The Lancet. Oncology.

The diagnosis and management of gastric cancer: expert discussion and recommendations from the 12th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2010.

R. Labianca, D. Kerr, K. Haustermans, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Time course of regorafenib-associated adverse events in the phase III CORRECT study

M. Ychou, R. Goldberg, H. Lenz, 2013 .

Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC)

Daniel J. Sargent, Olivier Bouché, Alberto Sobrero, 2012 .

Duration of Adjuvant Doublet Chemotherapy (3 or 6 months) in Patients With High-Risk Stage II Colorectal Cancer

R. Labianca, E. Oki, T. Yamanaka, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Methotrexate resistant cells as targets for selective chemotherapy.

S. Srimatkandada, J. Bertino, A. Sobrero, 1985, Advances in enzyme regulation.

Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.

R. Labianca, J. Berlin, K. Haustermans, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials.

R. Labianca, D. Sargent, M. Buyse, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.

R. Labianca, V. Torri, A. Bardelli, 2020 .

Studies on Hemopoietic Stem Cells in Mice Treated with Testosterone Propionate and Anticancer Drugs

A. Sobrero, I. Pannacciulli, G. Massa, 1982, Tumori.

S. Barni, R. Labianca, L. Frontini, 2019, Scientific Reports.

M. Piccart, U. Dafni, E. D. de Vries, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Raising the Bar for Antineoplastic Agents: How to Choose Threshold Values for Superiority Trials in Advanced Solid Tumors

D. Sargent, P. Bruzzi, A. Sobrero, 2014, Clinical Cancer Research.

Pancreatic cancer treatment and research: an international expert panel discussion.

J. Berlin, E. Van Cutsem, M. Ducreux, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of sunitinib as second-line treatment for advanced gastric cancer

Y. Bang, Yoon-Koo Kang, L. Shen, 2010, Investigational New Drugs.

Incremental advance or seismic shift? The need to raise the bar of efficacy for drug approval.

P. Bruzzi, A. Sobrero, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of glutaraldehyde treated autologous human erythrocytes for hepatic targeting of doxorubicin.

E. Zocchi, M. Tonetti, A. Sobrero, 1992, Advances in experimental medicine and biology.

The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012

R. Labianca, M. Büchler, J. Berlin, 2013 .

Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro.

J. Bertino, W. Bornmann, D. Debernardis, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

R. Labianca, J. Meyerhardt, D. Sargent, 2018, The New England journal of medicine.

Endogenous thymidine and hypoxanthine are a source of error in evaluating methotrexate cytotoxicity by clonogenic assays using undialyzed fetal bovine serum.

J. Bertino, A. Sobrero, 1986, International journal of cell cloning.

Current opinion on optimal treatment for colorectal cancer

N. Pavlakis, D. Haller, D. Cunningham, 2013, Expert review of anticancer therapy.

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

W. Scheithauer, H. Lenz, A. Zubel, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer.

R. Rosso, G. Rollandi, S. Mammoliti, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.

S. Barni, R. Labianca, V. Torri, 2007, Journal of the National Cancer Institute.

Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials

A. Degramont, J. Meyerhardt, C. Bokemeyer, 2022, JNCI Cancer Spectrum.

LBA25 FRESCO-2: A global phase III multiregional clinical trial (MRCT) evaluating the efficacy and safety of fruquintinib in patients with refractory metastatic colorectal cancer

R. García-Carbonero, T. Yoshino, S. Lonardi, 2022, Annals of Oncology.

Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel.

M. Ychou, E. Van Cutsem, B. Nordlinger, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy.

F. Maley, D. Debernardis, C. Baldo, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.

R. Labianca, J. Meyerhardt, V. Torri, 2020, The Lancet. Oncology.

Prognostic role of Ape/Ref-1 subcellular expression in stage I-III breast carcinomas.

G. Tell, F. Puglisi, C. di Loreto, 2002, Oncology reports.

Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies.

M. Ychou, E. Van Cutsem, H. Lenz, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequence-dependent synergism between dichloromethotrexate and cisplatin in a human colon carcinoma cell line.

J. Bertino, A. Sobrero, 1985, Cancer treatment reports.

Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial

R. Salazar, E. Van Cutsem, J. Tabernero, 2013, Clinical Cancer Research.

Rechallenge with anti-EGFR therapy to extend the continuum of care in patients with metastatic colorectal cancer

C. Montagut, A. Sobrero, S. Stintzing, 2023, Frontiers in Oncology.

Evaluation of Doxorubin Toxicity on Normal Hemopoietic Stem Cells

A. Sobrero, I. Pannacciulli, G. Massa, 1981, Tumori.

Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).

R. Labianca, L. Collette, A. Carrato, 2008, European journal of cancer.

FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial.

S. Barni, R. Labianca, L. Rimassa, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Design and rationale for novel antifolates.

J. Bertino, A. Sobrero, E. Mini, 1987, NCI monographs : a publication of the National Cancer Institute.

Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus.

L. Påhlman, J. Vauthey, E. Van Cutsem, 2015, Cancer treatment reviews.

Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study.

S. Barni, R. Labianca, C. Boni, 2014, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Optimal treatment of metastatic colorectal cancer

A. Sobrero, A. Pessino, 2006, Expert review of anticancer therapy.

The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies

E. Van Cutsem, J. Tabernero, A. Santoro, 2005, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.

R. Labianca, V. Torri, V. Zagonel, 2019, European journal of cancer.

Does chemotherapy prior to liver resection increase the potential for cure in patients with metastatic colorectal cancer? A report from the European Colorectal Metastases Treatment Group.

A. Carrato, V. Georgoulias, M. Ychou, 2007, European journal of cancer.

Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis

E. Van Cutsem, J. Tabernero, R. Mayer, 2020, ESMO Open.

Maximising clinical benefit with adequate patient management beyond the second line in mCRC

E. Van Cutsem, G. Prager, D. Arnold, 2019, ESMO Open.

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients

S. Barni, R. Labianca, L. Frontini, 2017, British Journal of Cancer.

Current Issues in Adjuvant Treatment of Stage II Colon Cancer

D. Sargent, M. Buyse, C. Boni, 2006, Annals of Surgical Oncology.

Dacarbazine and fotemustine in advanced colorectal cancer.

R. Rosso, A. Sobrero, A. Guglielmi, 1993, European journal of cancer.

5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer

R. Rosso, A. Sobrero, B. Ligas, 1995, Cancer Chemotherapy and Pharmacology.

Phase II trial of 5-fluorouracil and the natural l isomer of folinic acid in the treatment of advanced colorectal carcinoma.

R. Labianca, P. Conte, R. Rosso, 1994, European journal of cancer.

ctDNA to Guide Treatment of Colorectal Cancer: Ready for Standard of Care?

S. Sciallero, A. Sobrero, A. Puccini, 2023, Current Treatment Options in Oncology.

Adjuvant Chemotherapy for Stage II Colon Cancer

A. Sobrero, V. Martelli, S. E. Rebuzzi, 2020, Cancers.

Phase II study of a triplet regimen in advanced colorectal cancer using methotrexate, oxaliplatin and 5-fluorouracil

S. Barni, R. Labianca, L. Frontini, 2004, British Journal of Cancer.

Rapid development of resistance to antifolates in vitro: possible clinical implication.

J. Bertino, A. Nicolin, R. Rosso, 1991, Journal of the National Cancer Institute.

Prognostic Impact of Early Treatment and Oxaliplatin Discontinuation in Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 11 Adjuvant Trials

R. Labianca, J. Meyerhardt, E. Oki, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized intermittent or continuous panitumumab plus FOLFIRI (FOLFIRI/PANI) for first-line treatment of patients (pts) with RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): The IMPROVE study.

G. Troncone, A. Avallone, A. Budillon, 2022, Journal of Clinical Oncology.

A new prognostic and predictive tool for shared decision making in stage III colon cancer.

A. Shields, P. Bruzzi, A. Grothey, 2020, European journal of cancer.

The urgent need to improve the tools to assess clinical benefit and value of cancer treatment.

P. Bruzzi, G. Bregni, A. Sobrero, 2017, European journal of cancer.

From trial highlights to clinical context: putting American Society of Clinical Oncology gastrointestinal news into practice.

A. Sobrero, G. Aprile, S. Lutrino, 2013, Future oncology.

The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007.

R. Labianca, D. Kerr, W. Scheithauer, 2008, Annals of Oncology.

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.

R. Labianca, D. Kerr, J. Berlin, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Guidelines for time-to-event end-point definitions in adjuvant randomised trials for patients with localised colon cancer: Results of the DATECAN initiative.

R. Labianca, J. Meyerhardt, M. Shah, 2020, European Journal of Cancer.

Khorana score and thromboembolic risk in stage II–III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial

S. Barni, R. Labianca, M. Moroni, 2020, Therapeutic advances in medical oncology.

You're Cured Till You're Not: Should Disease-Free Survival Be Used as a Regulatory or Clinical End Point for Adjuvant Therapy of Cancer?

J. Zalcberg, A. Sobrero, A. Pastorino, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemosensitivity of human tumor clonogenic cells simultaneously assayed in agar diffusion chambers and in a two-layer agar culture system.

A. Sobrero, J. Marsh, 1984, Cancer treatment reports.

Effects of high-dose methotrexate and leucovorin on murine hemopoietic stem cells.

A. Sobrero, I. Pannacciulli, G. Massa, 1982, Cancer research.

Intermittent versus continuous chemotherapy in advanced colorectal cancer: a randomised 'GISCAD' trial.

S. Barni, R. Labianca, G. Beretta, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy and safety results from IMblaze370, a randomised Phase III study comparing atezolizumab+cobimetinib and atezolizumab monotherapy vs regorafenib in chemotherapy-refractory metastatic colorectal cancer.

J. Tabernero, N. Segal, M. Fakih, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor shrinkage evaluation during and after preoperative doxorubicin and cyclophosphamide followed by docetaxel in patients with breast cancer.

M. Bazzocchi, A. Piga, V. Londero, 2004, Anticancer research.

Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in older patients: A subgroup analysis from the TOSCA trial.

S. Barni, R. Labianca, D. Amadori, 2021, European journal of cancer.

Current challenges and future perspectives in the medical treatment of solid tumours

A. Sobrero, M. D. Benedetto, 2008 .

Differential efficacy of trimetrexate (2,4-diamino-6-methyl-(3,4,5-trimethoxyanilino)methyl) quinazoline, JB-11, TMQ) and methotrexate (MTX) on human colon carcinoma and human leukemia cells in vitro

J. Bertino, A. Sobrero, E. Mini, 1985 .

Phase II study of 5-fluorouracil plus leucovorin and interferon alpha 2b in advanced colorectal cancer.

P. Bruzzi, A. Sobrero, L. Gallo, 1992, European journal of cancer.

Comparison of in vitro drug sensitivity by inhibition of tritium release from [5-3H]-2'-deoxyuridine and a clonogenic assay.

A. Nicolin, R. Rosso, A. Sobrero, 1990, Anticancer Research.

Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study)

V. Torri, M. Ychou, E. Van Cutsem, 2016, ESMO Open.

Efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-FU as first-line treatment for patients with metastatic colorectal cancer.

S. Clarke, S. Ackland, A. Sobrero, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Resectability of initially unresectable liver metastases from colorectal cancer should not be the primary end point of clinical trials.

A. Sobrero, G. Aprile, 2009, Gastrointestinal cancer research : GCR.

Capecitabine versus Bolus Fluorouracil plus Leucovorin (Folinic Acid) as Adjuvant Chemotherapy for Patients with Dukes’ C Colon Cancer

R. Labianca, D. Amadori, R. Ravasio, 2008, Clinical drug investigation.

TAS-102 versus placebo (PBO) in patients (pts) ≥65 years (y) with metastatic colorectal cancer (mCRC): An age-based analysis of the recourse trial.

H. Lenz, J. Tabernero, B. Tran, 2015 .

Standard indication of immunotherapy for the treatment of cancer.

A. Sobrero, E. Rovini, A. Guglielmi, 1992, Pharmacological research.

The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib

S. Barni, R. Labianca, V. Torri, 2015, Oncotarget.

Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal.

A. Sobrero, 2006, The Lancet. Oncology.

548PIMPACT OF BASELINE COVARIATES AND PRIOR THERAPY ON THE EFFICACY OF SECOND-LINE PANITUMUMAB (PMAB) + FOLFIRI VS FOLFIRI TREATMENT.

E. Van Cutsem, F. Lordick, C. Punt, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumor measurements on computed tomographic images of non-small cell lung cancer were similar among cancer professionals from different specialties.

M. Bazzocchi, G. Fasola, O. Belvedere, 2004, Journal of clinical epidemiology.

gastrointestinal tumours, colorectalNintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study

H. Lenz, J. Tabernero, F. Ciardiello, 2016 .

Time required to start multicentre clinical trials within the Italian Medicine Agency programme of support for independent research

R. Labianca, L. Frontini, Antonio Pepe, 2015, Journal of Medical Ethics.

Final results of study 20050181: A randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second‑line treatment (tx) of metastatic colorectal cancer (mCRC).

F. Lordick, M. Ducreux, Y. Hotko, 2012 .

Abstract CT263: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: The PEGASUS trial

R. Labianca, V. Torri, M. Fassan, 2020 .

Sorafenib plus chemotherapy versus chemotherapy alone in advanced pancreatic cancer: A randomized phase II trial.

S. Barni, R. Labianca, R. Berardi, 2010 .

FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer.

J. Tabernero, T. Yoshino, A. Dasari, 2021, Future oncology.

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

J. Krauss, M. Ducreux, J. Tabernero, 2023, The Lancet.

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients

R. Labianca, L. Frontini, V. Zagonel, 2017, British Journal of Cancer.

A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation

R. Labianca, P. Tagliaferri, V. Catalano, 2007, British Journal of Cancer.

Results of a Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial (CORRECT) of Regorafenib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients with Metastatic Colorectal Cancer (MCRC) who have Progressed after Standard Therapies

M. Ychou, A. Grothey, H. Lenz, 2012 .

Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel.

M. Ychou, B. Nordlinger, T. Gruenberger, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

W. Oyen, R. Labianca, W. Scheithauer, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial.

E. Van Cutsem, A. Benson, J. Tabernero, 2015, European journal of cancer.

Current opinion on optimal treatment for colorectal cancer

N. Pavlakis, D. Haller, D. Cunningham, 2013, Expert review of anticancer therapy.

A tribute to biologics in advanced colorectal cancer treatment.

A. Sobrero, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer.

F. Lordick, M. Ducreux, Y. Hotko, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Association of skin toxicity (ST) severity with clinical outcomes and health-related quality of life (HRQoL) with panitunumab (Pmab)

B. Neyns, Y. Humblet, M. Peeters, 2007 .

Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of 800 patients in a randomized phase III trial (EPIC)

W. Scheithauer, A. Zubel, J. Maurel, 2005 .

Duration of Adjuvant Chemotherapy for Stage III Colon Cancer

R. Labianca, J. Meyerhardt, D. Sargent, 2018, The New England journal of medicine.

3542 POSTER Preliminary results from a phase II study of sunitinib as second-line treatment for advanced gastric cancer

Y. Bang, Yoon-Koo Kang, H. Chung, 2007 .

Adjuvant chemotherapy in the treatment of colon cancer: randomized multicenter trial of the Italian National Intergroup of Adjuvant Chemotherapy in Colon Cancer (INTACC).

C. Boni, F. di Costanzo, M. Tonato, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer (mCRC): Interim safety data from the global Aflibercept Safety and Quality-of-Life Program (ASQoP and AFEQT) in patients age 65 or older.

D. Ferry, L. Ciuffreda, J. Taieb, 2015 .

V. Heinemann, J. Taieb, A. Sobrero, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Ziv-aflibercept (Z) in combination with FOLFIRI for second-line treatment of patients (pts) with metastatic colorectal cancer (mCRC): Interim safety data from the global aflibercept safety and quality-of-life program in pts pretreated with bevacizumab (B).

D. Ferry, S. Siena, J. Taieb, 2014 .

U. Dafni, J. Kerst, A. Sobrero, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Uptake and metabolism of 5,8-dideazaisofolic acid in human colon carcinoma cells.

J. Bertino, A. Sobrero, J. McGuire, 1988, Biochemical pharmacology.

Mechanism of action of 5,8-dideazaisofolic acid and other quinazoline antifols in human colon carcinoma cells.

J. Bertino, A. Sobrero, J. Hynes, 1987, Cancer research.

546PTUMOUR SHRINKAGE AND RESPONSE OUTCOMES DURING SECOND-LINE PANITUMUMAB (PMAB) + FOLFIRI VS FOLFIRI TREATMENT.

F. Lordick, C. Punt, M. Ducreux, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Randomised, open-label, phase II trial of paclitaxel, gemcitabine and cisplatin versus gemcitabine and cisplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium.

V. Lorusso, M. de Lena, M. Lena, 2005, Oncology Report.

Sidedness influences prognosis in colon cancer patients receiving an adjuvant therapy. A GISCAD analysis from three randomized trials including 5234 patients.

R. Labianca, L. Frontini, A. Zaniboni, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.

Joon-Oh Park, M. Buyse, Y. Bang, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients

R. Labianca, L. Frontini, V. Zagonel, 2017, British Journal of Cancer.

Phase III trial comparing 3-6 months of adjuvant FOLFOX4/XELOX in stage II-III colon cancer: safety and compliance in the TOSCA trial.

S. Barni, R. Labianca, L. Rimassa, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Oxaliplatin-Based Adjuvant Chemotherapy in Older Patients With Stage III Colon Cancer: An ACCENT/IDEA Pooled Analysis of 12 Trials.

S. Lonardi, A. Sobrero, I. Souglakos, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts.

J. Meyerhardt, A. Sobrero, J. Souglakos, 2024, European journal of cancer.

Subgroup analyses of safety and efficacy by number and types of prior lines of treatment in FRESCO-2, a global phase III study of fruquintinib in patients with refractory metastatic colorectal cancer.

J. Tabernero, T. Satoh, Rajash Pallai, 2023, Journal of Clinical Oncology.